Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ApoE Mounts A Comeback In Alzheimer’s

This article was originally published in Start Up

Executive Summary

New research has identified ApoE as a potential direct regulator of transcription, suggesting a broad role for the molecule in the study of Alzheimer’s disease that could explain why the usual strategies of trying to break up accumulations of amyloid beta or regulate tau hyperphosphorylation have failed to adequately treat symptoms or cure the disease.

You may also be interested in...



Targeting BRCA1 And DNA Repair In Alzheimer’s To Prevent Or Reverse Symptoms

New research has shown that levels of the DNA repair protein BRCA1 are reduced in key parts of neurons after amyloid formation. The findings are consistent with the amyloid hypothesis and could prove to be an effective way to help prevent or reverse the symptoms of Alzheimer’s disease and other neurodegenerative diseases.

Alzheimer’s R&D In Brief: Roche’s Crenezumab Misses Endpoints, Novartis Plans Large New Genetic Study

In data presented at the Alzheimer's Association International Conference in Copenhagen, held July 12-17, Roche’s anti-amyloid beta antibody misses endpoints in two Phase II studies, but there were some promising signs of efficacy.

Autophagy Mechanism In Schizophrenia Revealed

Most of the current industry interest in autophagy – a mechanism cells use to degrade and remove damaged material – is centered on its role as a cancer drug target, but autophagy is also a neuroprotective mechanism. Now, a research team has shown its involvement in schizophrenia, opening the door for new drug and diagnostic development efforts.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel